Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
The researchers are testing adalimumab, a treatment which blocks tumor necrosis factor (TNF),
to see if it changes levels of urine biomarker levels (TIMP1 and MCP1). The outcomes may help
develop individualized treatment options for future patients with TNF driven Focal segmental
glomerulosclerosis (FSGS) or minimal change disease (MCD).